OPGN - OPGEN INC
Previous close
1.96
1.960 100.000%
Share volume: 0
Last Updated: Mon 19 Aug 2024 08:10:11 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
Fundamental analysis
23%
Profitability
43%
Dept financing
16%
Liquidity
42%
Performance
0%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
-8.04%
6 Months
-28.79%
1 Year
-58.41%
2 Year
1,307.69%
Key data
Stock price
$1.96
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.44 - $9.90
52 WEEK CHANGE
-$58.41
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
Company detail
CEO: Oliver Schacht
Region: US
Website: opgen.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: opgen.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
OpGen, Inc. engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen.
Recent news